Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) have been given a consensus rating of "Buy" by the six analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $22.17.
A number of brokerages have recently weighed in on PHAT. The Goldman Sachs Group lowered their target price on Phathom Pharmaceuticals from $18.00 to $12.00 and set a "neutral" rating on the stock in a research note on Monday. Craig Hallum reiterated a "buy" rating on shares of Phathom Pharmaceuticals in a research note on Friday, March 7th. Cantor Fitzgerald upgraded Phathom Pharmaceuticals to a "strong-buy" rating in a research note on Tuesday, February 25th. Needham & Company LLC restated a "buy" rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research note on Thursday, March 6th. Finally, HC Wainwright restated a "buy" rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research note on Friday, March 7th.
View Our Latest Stock Analysis on PHAT
Insider Activity at Phathom Pharmaceuticals
In other news, insider Terrie Curran sold 19,109 shares of Phathom Pharmaceuticals stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $6.59, for a total value of $125,928.31. Following the completion of the transaction, the insider now directly owns 360,465 shares of the company's stock, valued at approximately $2,375,464.35. This trade represents a 5.03 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Molly Henderson sold 6,583 shares of Phathom Pharmaceuticals stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $6.59, for a total value of $43,381.97. Following the completion of the transaction, the chief financial officer now directly owns 93,546 shares of the company's stock, valued at approximately $616,468.14. This trade represents a 6.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 35,987 shares of company stock valued at $240,551 in the last 90 days. 24.10% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Phathom Pharmaceuticals
A number of hedge funds have recently added to or reduced their stakes in PHAT. Jennison Associates LLC raised its holdings in Phathom Pharmaceuticals by 20.4% during the 4th quarter. Jennison Associates LLC now owns 7,062,507 shares of the company's stock valued at $57,348,000 after acquiring an additional 1,196,118 shares during the period. Vanguard Group Inc. raised its holdings in Phathom Pharmaceuticals by 3.1% during the 4th quarter. Vanguard Group Inc. now owns 2,779,561 shares of the company's stock valued at $22,570,000 after acquiring an additional 83,238 shares during the period. Portolan Capital Management LLC raised its holdings in Phathom Pharmaceuticals by 50.4% during the 3rd quarter. Portolan Capital Management LLC now owns 1,699,918 shares of the company's stock valued at $30,735,000 after acquiring an additional 569,829 shares during the period. Wasatch Advisors LP raised its holdings in Phathom Pharmaceuticals by 531.3% during the 4th quarter. Wasatch Advisors LP now owns 1,558,928 shares of the company's stock valued at $12,658,000 after acquiring an additional 1,311,986 shares during the period. Finally, Checkpoint Capital L.P. raised its holdings in Phathom Pharmaceuticals by 71.9% during the 3rd quarter. Checkpoint Capital L.P. now owns 1,504,307 shares of the company's stock valued at $27,198,000 after acquiring an additional 629,307 shares during the period. Institutional investors and hedge funds own 99.01% of the company's stock.
Phathom Pharmaceuticals Trading Up 4.5 %
NASDAQ:PHAT traded up $0.19 on Monday, hitting $4.41. The company's stock had a trading volume of 1,235,717 shares, compared to its average volume of 950,042. The stock has a fifty day moving average of $6.02 and a two-hundred day moving average of $10.94. The firm has a market capitalization of $301.54 million, a P/E ratio of -0.78 and a beta of 0.63. Phathom Pharmaceuticals has a one year low of $4.08 and a one year high of $19.71.
About Phathom Pharmaceuticals
(
Get Free ReportPhathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
Recommended Stories
Before you consider Phathom Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phathom Pharmaceuticals wasn't on the list.
While Phathom Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
